Entinostat
- Generic Name
- Entinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20N4O3
- CAS Number
- 209783-80-2
- Unique Ingredient Identifier
- 1ZNY4FKK9H
- Background
Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.
- Indication
联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer
- First Posted Date
- 2023-06-12
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT05898828
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
- Conditions
- Interventions
- First Posted Date
- 2021-09-23
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT05053971
- Locations
- 🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸University of Florida Health Science Center - Gainesville, Gainesville, Florida, United States
🇺🇸University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers
- First Posted Date
- 2021-01-14
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 107
- Registration Number
- NCT04708470
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread
- First Posted Date
- 2020-11-17
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 3
- Registration Number
- NCT04631029
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
- First Posted Date
- 2020-03-05
- Last Posted Date
- 2022-01-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1
- Registration Number
- NCT04296942
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Window of Opportunity Study of Pembrolizumab Alone and in Combinations in Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03978624
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas
- Conditions
- Advanced LymphomaAnn Arbor Stage III T-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV T-Cell Non-Hodgkin LymphomaRefractory Malignant Solid NeoplasmAnn Arbor Stage III B-Cell Non-Hodgkin LymphomaAnn Arbor Stage IV B-Cell Non-Hodgkin LymphomaRefractory LymphomaRefractory T-Cell Non-Hodgkin LymphomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8
- Interventions
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2020-09-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT03925428
Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers
- Conditions
- Ovarian Clear Cell AdenocarcinomaRecurrent Endometrial CarcinomaFallopian Tube CarcinosarcomaFallopian Tube Endometrioid AdenocarcinomaHigh Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaOvarian CarcinosarcomaPrimary Peritoneal Serous AdenocarcinomaFallopian Tube CancerFallopian Tube Clear Cell Adenocarcinoma
- Interventions
- First Posted Date
- 2019-04-23
- Last Posted Date
- 2022-04-04
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT03924245
- Locations
- 🇺🇸
University of Kansas Cancer Center, Kansas City, Kansas, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Combination of Entinostat and Enzalutamide in Advanced Prostate Cancer
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2021-08-02
- Lead Sponsor
- George Washington University
- Target Recruit Count
- 6
- Registration Number
- NCT03829930
- Locations
- 🇺🇸
George Washington University - Medical Faculty Associates, Washington, District of Columbia, United States
An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma
- First Posted Date
- 2018-12-05
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT03765229
- Locations
- 🇺🇸
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.